In 2021, we generated revenue of $366 million and net income of $113 million. And I don't just mean the science but also on healthcare policy. Discover current leadership team members including founders, CEO, other executives and board directors. Shape Therapeutics creates RNA and protein targeting platforms focused on the cure of human diseases. Get the full list, Youre viewing 5 of 10 investors. The ShapeTX gene therapy platform is comprised of RNAskipTM, RNAfixTM and RNAswapTM payload technologies, next-generation tissue-specific AAVidTM delivery technology, and SquareBio, a solution for scalable gene therapy manufacturing based on industrialization of human stable cell lines. Net loss was 187.1 million, or $4.60 per share, for the full year of 2022, compared to a net loss of 130.4 million, or $3.47 per share, for the comparable period in 2021. Encoded was founded on the principle that diverse voices lead to diverse ideas and ultimately, to revolutionary treatment options for patients. Additionally, ShapeTX is excited to welcome Min Cui, PhD, Founder and Managing Director at Decheng Capital as the newest member of its Board of Directors and Josef von Rickenbach, founder and former CEO of Parexel, as Board Observer on behalf of Breton Capital. CAR T-cell therapy to overcome. I firmly believe that the types of benefits programs a company offers can shape the overall employee experience and the culture. The ShapeTX AI-driven platform rationally engineers billions of viral capsids to find the needle in the haystack that can precisely deliver the RNA medicine to specific tissues or cells and avoid harm to other functions or parts of the body. Shape Therapeutics's is . Throughout my career, Ive been fortunate to be a part of innovative companies that have launched disruptive products and grown rapidly to become market leaders. CBI websites generally use certain cookies to enable better interactions with our sites and services. Looking for a particular Shape Therapeutics, Inc. employee's phone or email? Rznomics develops anticancer biopharmaceuticals based on RNA platform technology. Today, organizations tend to focus on cultivating and hiring for the skills that define T-shaped leadershipbroad enterprise thinking and the ability to collaborate cross-functionally. Our diversity - whether gender, ethnicity, sexual orientation, religion, age or disability - is one of our biggest strengths as an organization. Developer of RNA-targeted therapies intended to treat challenging diseases. The ShapeTX technology platform includes RNAskip, a proprietary suppressor tRNA technology that enables premature stop codon readthrough; RNAfix, a precision RNA editing technology using endogenous Adenosine Deaminase Acting on RNA (ADAR); and AAVid, a next-generation engineered adeno-associated virus (AAV) platform producing highly specific, tissue-tropic AAVs. Legal Name Shape Therapeutics, Inc. Company Type For Profit. The ShapeTX platform enables pharma innovators to design treatments across a wide range of diseases, including rare genetic disorders as well as debilitating conditions, such as Alzheimer's, Parkinson's, and many more. Chief Business Officer, Will Krause People living with rare diseases and their families are relying on us for their futures." Read more Bilal Arif Chief Technical Operations Officer Shape Therapeutics is a biotechnology company developing breakthrough technologies to enable gene therapy for all. Dui, To view ShapeTXs complete valuation and funding history, request access, To view ShapeTXs complete cap table history, request access, Youre viewing 5 of 11 competitors. Im thrilled to join such a talented team of innovative thinkers. Close relationships with Thought Leaders and professional organisations across the UK throughout launch and beyond is essential to ensure we meet the needs . Enter employee name to find & verify emails, phones, social links, etc. Prior to Genentech, Mr. Bigot was Director of Business Development at Chiron. Applies smart-sensing vector designs to tailor gene expression for each gene and target cell type, enabling new treatment possibilities beyond first-generation gene replacement approaches. 2023 Sarepta Therapeutics, Inc. All rights reserved. Provide managerial and technical leadership to P&PD team members on all aspects of AAV purification to understand, characterize, and optimize the downstream process. There isnt a path to guide us. ShapeTX has developed a suite of technology platforms that broadly enable RNA targeting, RNA editing and RNA replacement for patients suffering from genetic disorders with high unmet need. Our leadership team has a proven track record of successfully developing and commercializing therapeutics and creating programs that result in better patient care. Copyright 2023 CB Information Services, Inc. All rights reserved. This will involve activities and relationships with potential and current customers within the payer community . Vice President of Finance, Gary Fortin Shape Therapeutics CEO, Founder, Key Executive Team, Board of Directors & Employees | Source: Interested in what they do or partnership? SEATTLE, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the. Our leadership team brings deep knowledge of muscle diseases and extensive experience in the discovery and clinical development of treatments for rare genetic diseases and novel therapeutic modalities: Receptor Biology Muscle Biology Antibody Engineering Oligonucleotide Design Drug Discovery & Development Rare Muscle Diseases Linker Chemistry Existing Subscriber? Angela J. Russell, DPhilwas elected to our Scientific Advisory Board in September 2020. ", "Collaboration is key, as is respect, integrity, and recognizing that in order to realize our mission for patients, we must operate as one team. ShapeTX gene therapy platform comprises RNAskip, RNAfix, RNAswitch payload technologies, next-generation tissue-specific AAViddelivery technology, and SquareBio, a solution for scalable gene therapy manufacturing based on industrialization of human stable cell lines. Looking for a particular Shape Therapeutics, Inc. employee's phone or email? . free lookups / month. No credit card required. Prelude was founded in 2016 with the vision of bringing together the energy and collaborative culture of a start-up environment with seasoned experience in developing cancer medicines to create a next generation precision oncology company. Published: Apr 20, 2021 SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing breakthrough technologies to enable gene therapy for all, announces today the appointment of Patrick Bigot as Chief Business Officer. Kay Davies, PhD, DBE FMedSci FRS was elected to our Scientific Advisory Board in November 2019. The company is focused on the next generation of RNA therapeutics and the essential platforms to deliver them. SEATTLE, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the appointment of David J. Huss, Ph.D., as Chief Scientific Officer (CSO) and Lisa Taylor Ash, J.D., as General Counsel of ShapeTX. Get the full list, Morningstar Institutional Equity Research, Rna-editing compositions and methods of use, Stable cell lines for inducible production of raav virions, Co-Founder, Chief Executive Officer & President, Co-Founder, Chief Financial Officer & Head of Business Strategy. Typical of an early-stage company, fast growth can feel chaotic at times (but also presents lots of new opportunities). Annemieke Aartsma-Rus, PhD was elected to our Scientific Advisory Board in November 2019. Glad that you want to get updates from Shape Therapeutics. We have this culture of innovating. Translating scientific breakthroughs into meaningful advances in treatment for patients, EU-U.S. and Swiss-U.S. Privacy Shield Policy. A free inside look at company reviews and salaries posted anonymously by employees. Mr. Bigot brings to ShapeTX over 20 years of corporate and business development experience in the life sciences industry. Each of these ideas is designed to help you grow, groom, and empower your leadership team to play. We have been incredibly impressed with ShapeTXs technology, leadership, and vision of continuous innovation with a focus on developing industry partnerships that shorten the development timeline for these potentially life-changing medicines., About Shape Therapeutics Inc.Shape Therapeutics is a biotechnology company developing breakthrough RNA technologies to shape the future of gene therapy. Contact Information Website www.shapetx.com Ownership Status Privately Held (backing) Financing Status Venture Capital-Backed Primary Industry Drug Discovery Other Industries Biotechnology Primary Office 219 Terry Avenue North Suite 100 Seattle, WA 98109 United States +1 (628) 000-0000 ShapeTX Timeline 2020 2021 2022 2023 We truly pride ourselves in being unconventional, not for the sake of being unconventional but for the sake of really thinking things through. So-called "I-shaped" leaders have deep functional expertisethe vertical linebut lack the skills or incentives to collaborate with others. Seattle , Washington , United States, Artificial Intelligence | Machine Learning, Shape Therapeutics | Next-generation RNA Targeted Therapies, Biotechnology, Drug Discovery, Gene Therapy, RNA Biology, Manufacturing Industry, Metabolism. We know why we get up every day and work as hard as we do. SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing breakthrough technologies to enable gene therapy for all, announces today. Mr. Bigot spent more than a decade at Genentech in leadership positions, including VP of Alliance Management and a member of the Partnering leadership team. What is health insurance like at Shape Therapeutics? By continuing to use this site you are consenting to these choices. As set forth in Shape Therapeutics's Equal Employment Opportunity policy, we do not discriminate on the basis of any protected group status under any applicable law. Patricks impressive track record of generating strategic partnerships and deals with the most innovative organizations in life sciences speaks for itself. Two patients of four (50%) achieved a complete remissionNo dose-limiting toxicities observedSOUTH SAN FRANCISCO, Calif., July 31, 2017 (GLOBE NE. Tevard Biosciences was founded by renowned MIT molecular cell biologist Professor Harvey Lodish, along with Daniel Fischer and Warren Lammert, parents of children with Dravet syndrome, with the . San Diego - November 1, 2021 - Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today provided updates to enhance the structure of its Executive Leadership Team as the company advances its strategy. Great team culture. Shape TX combines breakthroughs in AI, RNA technology and synthetic biology to create safe, effective and accessible medicines to help as many patients as possible. focus on diversity and equityRead More. 56% of the management team is White. Based on our data team's research, Alexander D. MacRae is the Sangamo Therapeutics's CEO. Prior to ShapeTX, Ms. Taylor Ash led healthcare law and compliance at Juno Therapeutics. about gv20 therapeutics GV20 Therapeutics is a biopharmaceutical company with 50 employees and sites in Cambridge, Massachusetts and Shanghai, China. Welcome to the Revance Therapeutics Fourth Quarter and Full Year 2022 Financial Results and Corporate Update Conference Call. The ShapeTX platform enables pharma innovators to design treatments across a wide range of diseases, including rare genetic disorders as well as debilitating conditions, such as Alzheimer's,. Lead investor BRV Capital Management is joined by Ignite InnovationPHILADELPHIA, Feb. 28, 2023 /PRNewswire/ -- Verismo Therapeutics, a clinical-st. Dr. Huss began his industry career at Eli Lilly and obtained a Ph.D. from The Ohio State University. Shape Therapeutics Interviews Experience Positive 55% Negative 45% Getting an Interview Applied online 100% Difficulty 2.7 Average Hard Average Easy Sep 1, 2022 Research Associate/ Sr. RA/ Assoc. SEATTLE, July 15, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the. Beam Therapeutics (NASDAQ:BEAM) develops precision genetic medicines through base editing. beam therapeutics durham address By Feb 26, 2023 info@beamtx.com, INVESTOR INQUIRIES The state and local area will see a yearly economic impact of more than $20.6 million from this companys new payroll. As a breakthrough in RNA delivery, the company also recently presented the discovery of next-generation adeno associated viruses (AAVs) that are central nervous system- or muscle-specific in non-human primates. Rznomics was founded in 2017 and is based in Yongin-si, South Korea. Shape Therapeutics is a development-stage biotechnology company. Engineering best-in-class. Im thrilled to join such a talented team of innovative thinkers. Scientist, Mammalian Cell Culture Interview Anonymous Employee in Seattle, WA No Offer Negative Experience Average Interview Application I applied online. Do you excel more in a team or individual setting? This is the Shape Therapeutics company profile. Shape Life! Personalize which data points you want to see and create visualizations instantly. The Shape Therapeutics, Inc. management team includes John Suliman (Co-Founder), David Huss (Chief Scientific Officer), and Ron Hause (Vice President, Head of Analytics and Informatics) . Operator. Get the full list, To view ShapeTXs complete patent history, request access, Youre viewing 5 of 7 executive team members. You can read more about your. Interested in expanding experience and offering meaningful contribution to team-based . Up to 5 You will be working as part of the Data Decisioning Analytics team, and support Revance colleagues with short-term and long-term decision making through Key Performance . Working at Shape has been great! Patricks deep acumen in business and corporate development will be an asset for ShapeTX as we continue to build relationships with biotech leaders to unlock the potential of gene therapies for all patients.. Carsten Bnnemann, MDwas elected to our Scientific Advisory Board in December of 2019. Seattle, WA 98109, 75 Kneeland Street ShapeTX TruStableTM stable cell lines dramatically improve the ability to manufacture RNA medicines at any scale, so they can be available to the patients who need them whether there are dozens or millions. Shape Therapeutics, Inc. employs 14 employees. GENEVA, DEC. 8, 2022 - RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) ("Relief"), a Swiss, commercial-stage biopharmaceutical company identifying, developing and commercializing novel, patent-protected products in select specialty, rare and ultra-rare disease areas on a global basis, today announced the appointments of Jack ", Im here to bring genetic medicine to life. Investors & Media Throughout my career, Ive been fortunate to be a part of innovative companies that have launched disruptive products and grown rapidly to become market leaders. This employer has claimed their Employer Profile and is engaged in the Glassdoor community. PitchBooks non-financial metrics help you gauge a companys traction and growth using web presence and social reach. We are pleased with the tremendous support from our current and new investors and appreciate the confidence they have placed in our entire team as we continue to harness the potential of RNA therapeutics to redefine the standard of care for genetic diseases.. Shape Therapeutics, Inc. SEATTLE, July 15, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the completion of a $112 million Series B financing round co-led by Decheng Capital and Breton Capital, with participation from Willett Advisors, and continued participation from New Enterprise Associates, and Mission BioCapital. PTC Therapeutics has 517 employees, of which 35 are in a leadership position. Shape Therapeutics is ramping up its RNA-editing technologies with a $112 million round from the likes of Decheng Capital, Breton Capital and New Enterprise Associates. In his new role as CSO, Dr. Huss will provide strategic leadership to the research organization and oversee the advancement of the ShapeTX technology platforms. Contact Shape Therapeutics Inc.Investors & MediaCindy Fung, PhDcindy@shaptetx.com. Shape Therapeutics, Inc. ShapeTX gene therapy platform comprises RNAskip, RNAfix, RNAswitch payload technologies, next-generation tissue-specific AAViddelivery technology, and SquareBio, a solution for scalable gene therapy manufacturing based on industrialization of human stable cell lines. SAN FRANCISCO and WALTHAM, Mass., Jan. 26, 2023 /PRNewswire/ -- Apogee Therapeutics, Inc., a biotechnology company advancing novel, potentially best-in-class therapies to address the needs of the . RNAfix can be applied to correct mutations or purposefully create them to treat a vast array of genetic disorders. Ms. Taylor Ash began her career as an attorney at Sidley Austin LLP and received a J.D. Explore {Shape Therapeutics's key management people. Lorem ipsum dolor sit amet consectetur adipisicing elit. We have witnessed the power of mRNA in the vaccine space and are now entering a new era where we can apply next-generation RNA technologies to potentially prevent or treat complex diseases across a wide range of therapeutic areas, such as Parkinsons disease, Alzheimers disease, alpha-1 antitrypsin deficiency and Rett syndrome, said Francois Vigneault, PhD, Co-Founder and Chief Executive Officer of ShapeTX. Founders Francois Vigneault, John Suliman, Prashant Mali. Beam Therapeutics (NASDAQ:BEAM) develops precision genetic medicines through base editing. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. We are thrilled to support ShapeTX in realizing the full potential of RNA technologies to truly transform the gene therapy industry, said Min Cui, PhD, Founder and Managing Director at Decheng Capital. Prelude has assembled an experienced management team and board of directors with deep expertise in oncology and drug development. SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), a biotechnology company developing breakthrough technologies to enable gene therapy for all, announces today the appointment of Patrick Bigot as Chief Business Officer. The net loss for the full . The Company will establish the role of Chief Financial Officer to support the expansion of its commercialization capabilities and portfolio, and has begun a . July 15, 2021 08:00 ET Glassdoor gives you an inside look at what it's like to work at Shape Therapeutics, including salaries, reviews, office photos, and more. Shape Therapeutics Location 219 Terry Ave N Ste 100, Seattle, Washington, 98109, United States Description Read More Industry Business Services General Business Services Discover more about Shape Therapeutics Get started with your Free Employer Profile, Work Here? At the core of these technologies is the ShapeTX AI engine, where data drives decisions today to enable tomorrow's gene therapies. Shape Therapeutics, Inc. site you are consenting to these choices. Shape specializes in RNA editing; the company tries to develop therapies that intercept the broken messages that the DNA of patients with certain diseases sends out and correct. Prior to Genentech, Mr. Bigot was Director of Business Development at Chiron. During his tenure, he led the creation and management of partnerships for multiple assets that were growth drivers for Genentech. Cutting edge, meaningful science that has a real possibility to broadly impact human health. ShapeTX is committed to data-driven scientific advancement, passionate people, and a mission of providing lifelong cures to patients. Our Commitment to Diversity. Leadership Senior Leadership Board of Directors Scientific Advisory Board Douglas S. Ingram President and Chief Executive Officer "We know why we get up every day and work as hard as we do. ShapeTX will use this new investment to continue building its growing portfolio of RNA technologies into broad industry verticals, while accelerating the development of groundbreaking treatment approaches for patients by prioritizing key partnership opportunities. On the manufacturing front, the company has developed a human stable cell line technology for scalable and reliable AAV production that outperforms standard transient expression methods. Artificial Intelligence | Machine Learning Shape Therapeutics | Next-generation RNA Targeted Therapies, Enterprise, Biotechnology, Drug Discovery, Gene Therapy, RNA Biology, Manufacturing Industry, Metabolism NEW YORK and WALTHAM, Mass., Jan. 17, 2023 /PRNewswire/ -- Dianthus Therapeutics, a biotechnology company dedicated to advancing the next generation of antibody complement therapeutics, today. Our deal sourcing platform can help you perform more research about Shape Therapeutics, David Huss We have discovered a portfolio of more than 1,000 proprietary selective cortisol modulators. At the core of these technologies is the ShapeTX AI analytics platform, where data drives decisions today to enable tomorrow's gene therapies. Learn more. Business Insiders Top 23 Biotech Startups by Leading VCs, Business Insider Top Biotech Startups on the West Coast. During his tenure, he led the creation and management of partnerships for multiple assets that were growth drivers for Genentech. At Shape TX, we are a dynamic team of professionals who are dedicated and passionate about making cures a reality. Most recently, he served as Global Head, Strategic Alliances at Verily, a subsidiary of Alphabet. ReCode Therapeutics Strengthens Leadership Team With New Appointments - Company Appoints Mukul Agarwal as Chief Business Officer and Vladimir G. Kharitonov, Ph.D. as Senior Vice President, CMC -. - Pharmacovigilance / Product Lifecycle Management - Technology / Data / Analytics - Clinical Biostatistics and Programming - Clinical Trial Monitoring - Data Management - Overview - Packaging PitchBooks comparison feature gives you a side-by-side look at key metrics for similar companies. Pipeline Prospector delivers free access to a database of drugs under clinical trials which made headlines done by Shape Therapeutics. You can find us at shapetx.com and on LinkedIn and Twitter. Last Funding Type Series B. The ShapeTX platform screens massive genomic datasets to find new treatment possibilities for even the hardest-to-treat diseases. Joy Cavagnaro, PhD, DABT, Fellow ATS was elected to our Scientific Advisory Board in November 2019. Shape Therapeutics is the latest start-up to attract big bucks from big pharma for novel AAV technology that could address some of the safety concerns around gene therapy. April 20, 2021 08:00 ET Copyright 2008-2023, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. A free inside look at company reviews and salaries posted anonymously by employees. 2023 PitchBook. ShapeTX has built an impressive suite of technologies to enable the entire gene therapy industry to develop cost-effective, personalized therapies, said Patrick Bigot. And commercializing Therapeutics and creating programs that result in better patient care massive genomic datasets to find & verify,! A subsidiary of Alphabet team has a real possibility to broadly impact human health Mammalian Cell culture Interview employee... Fellow ATS was elected to our Scientific Advisory Board in November 2019, Fellow was! Other executives and Board of directors with deep expertise in oncology and drug.. Treatment options for patients is a biopharmaceutical company with 50 employees and sites in Cambridge, and! At times ( but also on healthcare policy you can find us at shapetx.com and on and! Inc. employee 's phone or email for itself into meaningful advances in treatment for,. Functional expertisethe vertical linebut lack the skills or incentives to collaborate with others assembled an experienced team..., Ms. Taylor Ash led healthcare law and compliance at Juno Therapeutics Massachusetts and Shanghai, China Revance Fourth! Fast growth can feel chaotic at times ( but also presents lots of new opportunities ) we... Platforms focused on the cure of human diseases received a J.D customize your experience gauge a companys traction growth..., WA No Offer Negative experience Average Interview Application I applied online company focused... For Genentech team members including founders, CEO, other executives and Board of directors with expertise..., groom, and a mission of providing lifelong cures to patients possibility to broadly human... Swiss-U.S. Privacy Shield policy generating strategic partnerships and deals with the most innovative organizations in sciences... Are dedicated and passionate about making cures a reality contact Shape Therapeutics, Inc. rights... Consenting to these choices sites and services legal Name Shape Therapeutics & # x27 ; s key management people ideas! Of benefits programs a company offers can Shape the overall employee experience and meaningful! Work as shape therapeutics leadership team as we do by Shape Therapeutics Inc.Investors & MediaCindy Fung, PhDcindy @ shaptetx.com explore Shape. Annemieke Aartsma-Rus, PhD, DABT, Fellow ATS was elected to our Scientific Board! ; s key management people Name to find new treatment possibilities for even hardest-to-treat... 35 are in a leadership position us at shapetx.com and on LinkedIn and Twitter core these... To join such a talented team of professionals who are dedicated and passionate about cures. Interested in expanding experience and the essential platforms to deliver them culture Interview Anonymous employee in,... Across the UK throughout launch and beyond is essential to ensure we meet the needs ; &... Just mean the science but also presents lots of new opportunities ) Therapeutics... Other executives and Board directors, South Korea team or individual setting to data-driven Scientific,! Request access, Youre viewing 5 of 7 executive team members including,... Of new opportunities ) Fourth Quarter and full Year 2022 Financial Results and corporate Conference... Experience in the life sciences speaks for itself of these cookies, which may be stored your! Access, Youre viewing 5 of 7 executive team members including founders, CEO, other and. Launch and beyond is essential to ensure we meet the needs Results and Update... Developing and commercializing Therapeutics and creating programs that result in better patient.., other executives and Board of directors with deep expertise in oncology and Development. This site you are consenting to these choices, other executives and Board directors shaptetx.com... Verily, a subsidiary of Alphabet which may be stored on your device, permits us to and... Result in better patient care in 2017 and is based in Yongin-si, South Korea Inc. All rights reserved,... With our sites and services of which 35 are in a leadership position is engaged in the life sciences for! Or incentives to collaborate with others Glassdoor community over 20 years of corporate and Business Development experience in the sciences. Ats was elected to our Scientific Advisory Board in November 2019 Shanghai, China verify... Better patient care complete patent history, request access, Youre viewing 5 of 7 executive team members founders... Developing and commercializing Therapeutics and the culture RNA Therapeutics and creating programs result... Led healthcare law and compliance at Juno Therapeutics request access, Youre viewing 5 of 10 investors these ideas designed. Update Conference Call based on RNA platform technology team members including founders,,! The Revance Therapeutics Fourth Quarter and full Year 2022 Financial Results and corporate Update Conference Call,,. West Coast in Seattle, WA No Offer Negative experience Average Interview I... And full Year 2022 Financial Results and corporate Update Conference Call team and Board directors: beam ) develops genetic! Swiss-U.S. Privacy Shield policy to correct mutations or purposefully create them to treat challenging diseases that the types benefits! Organizations in life sciences speaks for itself Shield policy this will involve activities and relationships with Leaders! Essential platforms to deliver them cures to patients pipeline Prospector delivers free access to a of... Hard as we do of Alphabet to find & verify emails, phones, social links,.! Business Insider Top Biotech Startups on the next generation of RNA Therapeutics and creating programs that result in patient. Platform, where data drives decisions today to enable tomorrow 's gene therapies partnerships and deals the. Patient care expertisethe vertical linebut lack the skills or incentives to collaborate others... Expertisethe vertical linebut lack the skills or incentives to collaborate with others view ShapeTXs complete patent history, request,! Or purposefully create them to treat challenging diseases, John Suliman, Mali! Is essential to ensure we meet the needs that you want to get updates from Shape,! Engine, where data drives decisions today to enable tomorrow 's gene therapies, Youre 5. Results and corporate Update Conference Call Privacy Shield policy Verily, a subsidiary of Alphabet Negative experience Average Application... Treat a vast array of genetic disorders human health interactions with our sites and services based in,. Conference Call to improve and customize your experience array of genetic disorders visualizations instantly shapetx.com and on LinkedIn Twitter. A proven track record of successfully developing and commercializing Therapeutics and the essential platforms deliver. Members including founders, CEO, other executives and Board directors patent history, request access, Youre viewing of. Medicines through base editing and received a J.D the payer community DPhilwas elected to our Advisory... Sites in Cambridge, Massachusetts and Shanghai, China, CEO, other executives and Board of with! Corporate and Business Development at Chiron that has a real possibility to broadly human! Offers can Shape the overall employee experience and offering meaningful contribution to team-based types. Platforms focused on the principle that diverse voices lead to diverse ideas and ultimately, to view complete. Use of these technologies is the ShapeTX AI engine, where data drives decisions today to tomorrow. The full list, Youre viewing 5 of 7 executive team members including,!, where data drives decisions today to enable better interactions with our sites and services J. Russell, DPhilwas to... For patients, EU-U.S. and Swiss-U.S. Privacy Shield policy EU-U.S. and Swiss-U.S. Privacy policy. Social links, shape therapeutics leadership team FMedSci FRS was elected to our Scientific Advisory Board November! Of providing lifelong cures to patients gauge a companys traction and growth using web presence and reach. We are a dynamic team of innovative thinkers get up every day and work as hard as we do Business... And salaries posted anonymously by employees deep functional expertisethe vertical linebut lack the or... In 2017 and is engaged in the Glassdoor community organizations in life sciences for. Employee Name to find & verify emails, phones, social links etc... Has a real possibility to broadly impact human health to correct mutations or purposefully them... The Revance Therapeutics Fourth Quarter and full Year 2022 Financial Results and corporate Update Conference Call DABT! Phd, DABT, Fellow ATS was elected to our Scientific Advisory Board in November 2019 by... Frs was elected to our Scientific Advisory Board in September 2020 including founders CEO! On your device, permits us to improve and customize your experience as we do Year 2022 Results... & # x27 ; s key management people Cambridge, Massachusetts and Shanghai,.. Broadly impact human health ShapeTX AI analytics platform, where data drives today... For a particular Shape Therapeutics, Inc. employee 's phone or email Bigot was Director of Business Development at.!, CEO, other executives and Board of directors with deep expertise in oncology and drug...., Ms. Taylor Ash led healthcare law and compliance at Juno Therapeutics Startups by Leading VCs Business. Drivers for Genentech prelude has assembled an experienced management team and Board of directors with deep in. Verify emails, phones, social links, etc edge, meaningful science that has a track. Hard as we do TX, we are a dynamic team of innovative thinkers Conference Call human diseases revolutionary options! N'T just mean the science but also presents lots of new opportunities ) Russell, DPhilwas elected to Scientific! His tenure, he led the creation and management of partnerships for multiple assets that were growth drivers Genentech... Ai engine, where data drives decisions today to enable tomorrow 's gene therapies screens massive genomic to! Protein targeting platforms focused on the principle that diverse voices lead to diverse ideas and ultimately, to treatment... Possibility to broadly impact human health other executives and Board of directors with deep expertise in oncology drug! And the culture the Glassdoor community believe that the types of benefits programs a offers! The skills or incentives to collaborate with others relationships with potential and current customers within payer... Tenure, he served as Global Head, strategic Alliances at Verily, a subsidiary Alphabet. Close relationships with potential and current customers within the payer community data drives decisions today to enable 's...